Acetyl-TP53 (K386) Antibody

What is the Acetyl-TP53 (K386) antibody and what does it specifically detect?

The Acetyl-TP53 (K386) antibody is a polyclonal antibody that specifically recognizes p53 protein only when acetylated at lysine 386. This antibody does not detect unmodified p53 or p53 with other post-translational modifications at this site. Most commercially available versions are rabbit polyclonal antibodies generated against synthetic peptides corresponding to the region surrounding the acetylated lysine 386 residue of human p53 .

The specificity is critical for researchers studying the functional consequences of this particular post-translational modification. The antibody recognizes endogenous levels of human p53 protein acetylated at K386, and some versions also detect mouse and rat p53 when acetylated at the corresponding residues .

What is the biological significance of p53 K386 acetylation?

The acetylation of p53 at K386 plays a crucial role in regulating p53's function as a transcription factor. This post-translational modification affects:

• DNA binding affinity - acetylation enhances p53's ability to bind to target gene promoters

• Transcriptional activity - K386 acetylation influences p53-mediated gene expression

• Protein stability - acetylation can affect p53 protein turnover

• Protein-protein interactions - modified p53 interacts differently with binding partners

Importantly, research has revealed a complex crosstalk between sumoylation and acetylation at K386. Sumoylation at K386 blocks subsequent acetylation by p300, whereas p300-acetylated p53 remains accessible for further modifications . This regulatory mechanism impacts p53's ability to bind DNA and activate transcription of target genes involved in cell cycle arrest, DNA repair, and apoptosis.

What are the validated applications for Acetyl-TP53 (K386) antibody?

Based on multiple manufacturer specifications, the Acetyl-TP53 (K386) antibody has been validated for several experimental applications:

For Western blot analysis, the antibody typically detects a primary band at approximately 53 kDa representing the full-length acetylated p53 protein, with some researchers reporting an additional band at around 43 kDa that may represent a processed form of the protein .

How should samples be prepared to best preserve the K386 acetylation signal?

Preserving acetylation marks requires specific sample preparation protocols:

• Cell lysis buffer considerations:

  • Include deacetylase inhibitors (e.g., sodium butyrate, trichostatin A, or nicotinamide) at appropriate concentrations

  • Use freshly prepared RIPA or NP-40 buffer with protease inhibitor cocktail

  • Maintain cold temperatures throughout processing (4°C)

• For Western blotting:

  • Avoid excessive heating of samples (limit to 5 minutes at 95°C)

  • Include 5-10% glycerol in loading buffer to stabilize proteins

  • Process samples quickly and avoid multiple freeze-thaw cycles

• For IHC/IF applications:

  • Perform fixation with 4% paraformaldehyde rather than harsher fixatives

  • Conduct heat-mediated antigen retrieval with sodium citrate buffer (pH 6.0)

  • Block with 3% BSA-PBS for 30 minutes at room temperature before primary antibody incubation

These precautions help maintain the integrity of the acetylation mark, which can be labile under certain conditions.

How does p53 K386 acetylation interact with other post-translational modifications of p53?

The relationship between K386 acetylation and other post-translational modifications represents a complex regulatory network:

• Sumoylation-Acetylation Crosstalk:
  Research has demonstrated that sumoylation of p53 at K386 blocks subsequent acetylation by p300. Conversely, p300-acetylated p53 remains accessible for further modifications . The sumoylation-deficient K386R protein exhibits higher transcriptional activity and enhanced binding to the endogenous p21 gene compared to wild-type p53 .

• Acetylation Patterns:
  K386 acetylation occurs within a cluster of C-terminal lysines (K370, K372, K373, K381, K382) that can be acetylated by different acetyltransferases including p300/CBP and PCAF. The pattern of acetylation across these sites determines functional outcomes.

• Phosphorylation Influence:
  Phosphorylation of serine and threonine residues in response to cellular stress can precede and promote acetylation events. For example, phosphorylation at S15 and S20 following DNA damage can enhance subsequent acetylation at C-terminal lysines.

What are the key technical challenges in detecting acetylated p53 at K386 and how can they be overcome?

Researchers face several challenges when detecting acetylated p53 at K386:

• Low abundance of acetylated form:

  • Solution: Use treatments that enhance acetylation (HDAC inhibitors like TSA or stress inducers like colchicine at 0.2ng/ml for 24h)

  • Consider immunoprecipitation to enrich the acetylated protein before detection

• Cross-reactivity concerns:

  • Solution: Validate antibody specificity using acetylation-deficient mutants (K386R)

  • Include proper negative controls (unacetylated p53) and positive controls (cells treated with HDAC inhibitors)

• Signal-to-noise ratio:

  • Solution: Optimize blocking conditions (5% BSA often works better than milk for phospho- and acetyl-specific antibodies)

  • Increase washing stringency and duration between antibody incubations

• Epitope masking due to protein-protein interactions:

  • Solution: Consider using different lysis conditions or include appropriate detergents

  • Test alternative antigen retrieval methods for IHC/IF applications

How can researchers experimentally distinguish the specific effects of K386 acetylation from other p53 acetylation sites?

To isolate the specific effects of K386 acetylation from other acetylation sites:

• Site-specific mutants:

  • Generate point mutants (K386R) that prevent acetylation at this site while maintaining other acetylation sites

  • Use K386Q acetylation-mimicking mutants for comparison

  • Create combinatorial mutants with other acetylation sites to assess synergistic effects

• Mass spectrometry approaches:

  • Perform targeted mass spectrometry to quantify the stoichiometry of acetylation at different lysine residues

  • Use parallel reaction monitoring (PRM) to specifically track K386 acetylation

• Sequential modification assays:

  • Employ in vitro systems to sequentially add specific modifications

  • As demonstrated in published research, the order of modifications affects outcomes—sumoylation at K386 blocks subsequent acetylation by p300, while p300-acetylated p53 remains accessible for further modifications

What are the essential controls when working with Acetyl-TP53 (K386) antibody?

Robust experimental design requires appropriate controls:

• Positive controls:

  • Cell lines treated with HDAC inhibitors to increase global acetylation levels

  • Specific cell types known to exhibit high levels of K386 acetylated p53 (HEK293T, HeLa, and A2780 cells have been validated)

  • Cells treated with colchicine (0.2ng/ml for 24h) show enhanced K386 acetylation

• Negative controls:

  • p53-null cell lines (e.g., H1299) or p53 knockdown samples

  • K386R mutant-expressing cells where acetylation at this site is prevented

  • Peptide competition assay using the synthetic acetylated peptide immunogen

• Antibody validation:

  • Confirm specificity by preincubating the antibody with the synthesized immunogenic peptide

  • Western blot should show primarily bands at 53 kDa and sometimes 43 kDa

  • Secondary-only controls for immunostaining to assess background

How can researchers investigate the functional consequences of p53 K386 acetylation?

To determine the functional impact of K386 acetylation:

• Gene expression analysis:

  • Compare transcriptional profiles of cells expressing wild-type p53 versus K386R (acetylation-deficient) or K386Q (acetylation-mimetic) mutants

  • Focus on known p53 target genes (p21, PUMA, BAX) using qRT-PCR or RNA-seq

• Chromatin immunoprecipitation (ChIP):

  • Use the Acetyl-TP53 (K386) antibody for ChIP to identify genomic regions bound by acetylated p53

  • Compare with total p53 ChIP to determine if acetylation affects binding to specific promoters

  • The K386R mutant has been shown to exhibit higher binding to the endogenous p21 gene compared to wild-type p53

• Protein-protein interaction studies:

  • Identify differential binding partners of acetylated versus non-acetylated p53 using immunoprecipitation followed by mass spectrometry

  • Investigate how K386 acetylation affects interaction with known p53 regulators like MDM2

• Cellular phenotype assays:

  • Assess cell cycle distribution, apoptosis rates, and DNA damage responses

  • Compare cells expressing wild-type p53 versus K386 mutants

How does the crosstalk between sumoylation and acetylation at K386 regulate p53 function?

The interplay between these modifications represents a sophisticated regulatory mechanism:

What are the emerging techniques for studying site-specific acetylation of p53?

Cutting-edge approaches for investigating K386 acetylation include:

• Genetic code expansion technology:

  • Direct incorporation of acetyl-lysine at position 386 during protein synthesis

  • Allows production of homogeneously acetylated p53 for biochemical and structural studies

• CRISPR-based approaches:

  • Creation of endogenous K386R or K386Q mutations to study physiological effects

  • Base editing to introduce specific mutations without double-strand breaks

• Advanced imaging techniques:

  • Proximity ligation assays (PLA) to visualize K386-acetylated p53 interactions with specific partners in situ

  • Super-resolution microscopy to track subcellular localization of specifically modified p53

• Single-cell analysis:

  • Single-cell proteomics to examine heterogeneity in p53 modification states

  • Correlation of modification patterns with cell fate decisions at the individual cell level

These emerging technologies offer unprecedented opportunities to understand the precise role of K386 acetylation in p53 function and cancer biology.

What experimental evidence supports the specificity of the Acetyl-TP53 (K386) antibody?

Multiple validation approaches confirm antibody specificity:

• Western blot analysis:

  • Detection of expected 53 kDa band in HEK293T and A2780 cell lysates

  • Enhanced signal following colchicine treatment (0.2ng/ml, 24h) in HEK293T, HeLa, and H9C2 cells

  • Absence of signal in p53-null or K386R mutant expressing cells

• Peptide competition assays:

  • Signal abolished when antibody is preincubated with the synthetic acetylated peptide immunogen

  • Maintained signal with non-acetylated peptide controls

• Immunohistochemistry validation:

  • Specific staining in human lung carcinoma tissue that is blocked by the synthetic peptide

  • Appropriate nuclear localization pattern consistent with p53 biology